Journal of Cancer Research and Therapeutics Close
 

Figure 2: Network graphs of check point inhibitors and their effect on survival at first line in Nonsmall cell lung cancer. (a) Check point inhibitors and their effect on overall survival at first line, (b) Check point inhibitors and their effect on progression-free survival at first line (Che=Chemotherapy, Pem: Pembrolizumab, Niv=Nivolumab, Ip=Ipilimumab phased, Ic=Ipilimumab concurrent, I=Ipilimumab, Ate=Atezolizumab)

Figure 2: Network graphs of check point inhibitors and their effect on survival at first line in Nonsmall cell lung cancer. (a) Check point inhibitors and their effect on overall survival at first line, (b) Check point inhibitors and their effect on progression-free survival at first line (Che=Chemotherapy, Pem: Pembrolizumab, Niv=Nivolumab, Ip=Ipilimumab phased, Ic=Ipilimumab concurrent, I=Ipilimumab, Ate=Atezolizumab)